Last reviewed · How we verify
ESL Tutti-Frutti taste
ESL works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4).
ESL works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). Used for Type 2 diabetes.
At a glance
| Generic name | ESL Tutti-Frutti taste |
|---|---|
| Also known as | Eslicarbazepine acetate (ESL) |
| Sponsor | Bial - Portela C S.A. |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
This inhibition increases the levels of incretin hormones, which in turn increases insulin release in response to meals and decreases glucagon levels in the circulation during the postprandial period. This results in lowering of glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Headache
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESL Tutti-Frutti taste CI brief — competitive landscape report
- ESL Tutti-Frutti taste updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI